Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts

Antiviral Therapy

Volumn 12, Issue 3, 2007, Pages 325-333

  Mocroft, Amanda ^a   Staszewski, Schlomo ^b   Weber, Rainer ^c   Gatell, José ^d   Rockstroh, Jurgen ^e   Gasiorowski, Jacek ^f   Panos, George ^g   Monforte, Antonella D'Arminio ^h   Rakhmanova, Aza ⁱ   Phillips, Andrew N ^a   Lundgren, Jens D ^j  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d HOSPITAL CLÍNIC   (Spain)

^e UNIVERSITY HOSPITAL BONN   (Germany)

^f WROCLAW MEDICAL UNIVERSITY   (Poland)

^g 1st IKA Hospital   (Greece)

^h Ospedale San Paolo   (Italy)

ⁱ Medical Academy Botkin Hospital   (Russian Federation)

^j HVIDOVRE HOSPITAL   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ARGENTINA; CD4 LYMPHOCYTE COUNT; EUROPE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; ISRAEL; LIVER DISEASES; MALE; MIDDLE AGED; NEVIRAPINE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 34249054728     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Washington, DC: Department of Health and Human Services; 10 October 2006. [Cited 6 November 2006]. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentsGL.pdf.
2. Viramune. Package insert. Revised 22 December 2003. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
3. Cattelan AM, Erne E, Salatino A, et al. Severe hepatic failure related to nevirapine treatment (letter). Clin Inf Dis 1999; 29:455-456.
4. Boxwell D, Haverkos H, Kukich S, et al. Serious adverse events attributed to nevirapine regimens for post exposure prophylaxis after HIV exposures - worldwide, 1997-2000. MMWR 2001; 49:1153-1156.
5. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use (letter). J AIDS 2004; 35:538-539.
6. Ananworanich J, Moor Z, Siangphoe U, et al. Incidence and risk factors for rash in Thai patients randomised to regimens with nevirapine, efavirenz or both drugs. AIDS 2005; 19:185-192.
7. th Conference on Retroviruses and Opportunistic Infections. 4-8 February 2001, Chicago, IL, USA. Abstract 19.
8. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
9. Mocroft A, Rockstroh J, Soriano V, et al. Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection? Antivir Ther 2005; 10:779-790.
10. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J AIDS 2003; 34 Suppl 1:S21-S33.
11. Dietrich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonucleoside reverse-transcriptase inhibitors. Clin Inf Dis 2004; 38 Suppl 2:S80-S89.
12. US Food and Drug Administration Center for Drug Evaluation and Research. FDA Public Health Advisory for nevirapine (Viramune). 11 January 2005. [Cited 31 May 2006]. Rockville MD: US Food and Drug Administration. Available from: http://www.fda.gov/cder/drug/advisory/nevirapine.htm.
13. Van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet 2004; 363:1253-1263.
14. th Interscience Conference on Antimicrobial Agents and Chemotherapy. 16-19 December 2005, Washington, DC, USA. Abstract LB-13.
15. Montaner JS, Cah P, Zala C, et al. Randomised, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. J AIDS 2003; 33:41-46.
16. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts (letter). AIDS 2005; 19:97-99.
17. Antinori A, Baldini F, Girardi E, et al. Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. AIDS 2001; 15:1579-1581.
18. Floridia M, Bucciardini R, Fragola V, et al. Risk factors and occurrence of rash in HIV-positive patients not receiving non-nucleoside reverse transcriptase inhibitor: Data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/microl.). HIV Med 2004; 5:1-10.
19. Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133:401-410.
20. The Antiretroviral Therapy in Lower Income Countries (ART-LINC) and ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1 infected patients in the first year of antiretroviral therapy: Comparisons between low-income and high-income countries. Lancet 2006; 367:817-824.